On heels of $100M raise, Annexon joins burgeoning IPO queue
Asian biopharma IPOs headline week that had three U.S. companies enter NASDAQ IPO queue
Two days after raising $100 million in a series D round heavy with crossover investors, Annexon has filed to go public on NASDAQ.
The filing adds to a burgeoning IPO queue and caps another busy week for newly public or soon-to-be public companies. Headlining the week were a pair of Asian biopharmas: SK Biopharmaceuticals Co. Ltd. (KRX:326030), which raised nearly $800 million on the Korea Exchange, and Gan & Lee Pharmaceuticals (Shanghai:603087). Gan & Lee’s shares rose sharply in their first day of trading on the Shanghai Stock Exchange and then gained the maximum allowed by the exchange for three consecutive days to close Thursday at RMB121.36, up RMB58.04 (92%) from its offering price (see “SK Becomes Korea’s Third-Largest Public Healthcare Company”; “Gan & Lee Hits Ceiling in First Day on Shanghai”)...